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Abstract 
Background: Transfusion with Plasmodium-infected blood represents a risk for malaria transmission, a rare but severe 
event. Several non-endemic countries implement a strategy for the screening of candidate blood donors including 
questionnaire for the identification of at-risk subjects and laboratory testing of blood samples, often serology-based, 
with temporary deferral from donation for individuals with a positive result. In Italy, the most recent legislation, issued 
in November 2015, introduced the use of serological tests for the detection of anti-Plasmodium antibodies.
Methods: In the absence of a gold standard for malaria serology, the aim of this work was to evaluate five commer-
cial ELISA kits, and to determine their accuracy (sensitivity and specificity) in comparison to immuno-fluorescence 
antibody test (IFAT), and their agreement (concordance of results). Serum samples from malaria patients or from sub-
jects with malaria history (N = 64), malaria naïve patients with other parasitic infections (N = 15), malaria naïve blood 
donors (N = 8) and malaria exposed candidate blood donors (N = 36) were tested.
Results: The specificity of all ELISA kits was 100%, while sensitivity ranged between 53 and 64% when compared to 
IFAT on malaria patients samples. When tested on candidate blood donors’ samples, ELISA kits showed highly variable 
agreement (42–94%) raising the possibility that the same individual could be included or excluded from donation 
depending on the test in use by the transfusion centre.
Conclusions: These preliminary results indicate how the lack of a gold standard for malaria serology must be taken 
into account in the application and future revision of current legislation. There is need of developing more sensitive 
serological assays. Moreover, the adoption of a unique serological test at national level is recommended, as well as the 
development of screening algorithms based on multiple laboratory tests, including molecular assays.
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Background
Transfusion-transmitted malaria (TTM) is an alterna-
tive accidental route of malaria infection caused by the 
transfusion of whole blood, or a blood component, from 
an infected donor harbouring Plasmodium parasites to a 
recipient. The infection may be responsible for the devel-
opment of severe clinical symptoms in the recipients, 
especially in malaria naïve individuals, and may become 
life threatening [1, 2].
Six species of Plasmodium are currently known to 
cause malaria in humans with 216 million new cases 
and 445,000 deaths estimated in 2016 [3]. Plasmodium 
falciparum, the most diffused species—especially in 
sub-Saharan Africa (SSA)—is responsible for the vast 
majority of severe and fatal cases. Plasmodium vivax, 
mainly present in Central and South America and South-
east Asia can also cause severe disease, although the 
fatality rate is lower compared to P. falciparum [4]. Inter-
estingly, P. vivax and Plasmodium ovale (the latter being 
mainly observed in SSA) have a dormant liver stage—
hypnozoite—which can relapse months or years after 
treatment completion; while the worldwide distributed 
Plasmodium malariae infection can persist indefinitely 
[5, 6]. More recently, the two zoonotic species Plasmo-
dium knowlesi and Plasmodium simium have also been 
associated with human malaria cases. The former usually 
infects macaque monkeys in Southeast Asia [7, 8], while 
the latter infects howler and capuchin monkeys and, very 
recently, has caused an outbreak of human malaria in 
southern Brazil [9].
In non-endemic countries, the identification of donors 
at risk of Plasmodium infection has become an important 
issue especially with the increased travelling of people 
and migratory phenomena, leading to the implemen-
tation of blood safety policies [10]. To avoid the risk of 
TTM, some countries (namely USA and Canada) have 
adopted a deferral policy, which, however, might also be 
associated with the loss of blood supply [5, 11]. In the 
effort to guarantee blood safety without affecting blood 
availability, most European countries have instead intro-
duced blood screening policies in order to reduce the 
deferral period for those individuals who come from 
or visited malaria endemic areas and thus considered 
at risk, although there is a lack of consensus regarding 
the length of deferral of donors with positive screening 
test results across countries [5, 12]. In Italy the relevant 
regulation (no. 219, October 2005) has been recently 
amended (November 2015), and currently requires indi-
viduals considered at risk based on donor questionnaire 
to be tested for anti-Plasmodium antibodies and, in case 
of a positive result, to be excluded from blood donation 
for 3 years [13].
In principle, a blood screening test could be based 
either on direct or indirect methods. Detection of Plas-
modium parasites on Giemsa-stained thick and thin 
blood smears by microscopic examination has been 
the gold standard for malaria diagnosis for over a cen-
tury, allowing both the determination of species and 
that of parasite density. The theoretical limit of detec-
tion of microscopy is 5  parasites/µl but sensitivity var-
ies according to the microscopist’s experience in the 
5–100  parasites/µl range [14]. Rapid diagnostic tests 
based on antigen detection via immunochromatographic 
methods have been introduced in malaria endemic coun-
tries to improve access to diagnosis and limit treatment 
to confirmed cases where microscopy is not accessible, 
but show limited sensitivity at parasite densities lower 
than 100  parasites/µl [15]. Nowadays, more sensitive 
(0.1–2  parasites/µl) diagnostic tools based on nucleic 
acid amplification tests detecting malaria parasite genetic 
material are available and are especially useful in order to 
detect asymptomatic subjects carrying parasites at sub-
microscopic densities [16].
Indirect methods for the detection of anti-Plasmodium 
antibodies include indirect immuno-fluorescence anti-
body test (IFAT), a well-established technique in sev-
eral European countries [5] which was recently (2017) 
discontinued from production from the manufacturer 
Biomérieux, and enzyme-linked immuno-sorbent assay 
(ELISA), now very popular in most laboratories. Detec-
tion of Plasmodium-specific antibodies has virtually no 
place in diagnosis of clinically acute malaria cases nor 
infection, while is among the diagnostic criteria used to 
determine chronic forms of malaria such as hyper reac-
tive malarial splenomegaly. Nonetheless, serological tests 
are recommended by the World Health Organization and 
the European Directorate for the Quality of Medicines 
for the screening of candidate blood donors considered at 
risk of carrying an asymptomatic Plasmodium infection 
[17, 18]. This choice is based on the supposedly higher 
sensitivity of serology, which lacks the detection limit of 
microscopy and other direct methods.
However, establishing sensitivity of serology is a chal-
lenging task, as the magnitude and longevity of Plas-
modium-specific antibody responses vary according 
to several host (e.g. age, length of residence in endemic 
country), parasite (e.g. parasite, strain, antigen) and envi-
ronmental (transmission level) factors [19, 20]. Such 
task is particularly challenging in the non-homogenous 
population of blood donors in non-endemic countries. 
Furthermore, an objective assessment of the sensitivity 
of the antibody detection techniques currently in use for 
blood safety purposes has been addressed by only few 
studies [20–22].
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The objective of this observational study was to evalu-
ate five commercial ELISA kits as a malaria screening 
tool of blood donors.
Methods
Study population
The retrospective study was carried out using archived 
serum samples from subjects recruited in two Italian 
laboratories. Serum samples (N = 64) obtained from 
38 patients hospitalized between 2014 and 2016 at 
the Centre for Tropical Diseases (CTD) of the IRCCS 
Sacro Cuore-Don Calabria Hospital (Negrar, Verona, 
Italy) were used. All subjects were either diagnosed 
with malaria by microscopy or had a previous history of 
malaria infection. Samples, previously tested by IFAT, 
were chosen based on IFAT titre, in order to cover a 
range of IFAT titres spanning from 0 to 1:10,240 (N = 8 
for each of titres 0, 20, 80, 160, 320, 640; N = 4 for each 
of titres 1280, 2560, 5120, 10,240). Samples with IFAT 
titre = 0 were obtained from patients with ascertained 
malaria infection at a very early stage of infection, when 
antibodies are not yet present. However, subsequent tests 
performed during hospitalization, showed a progressive 
increase in IFAT titre over time. Serum samples from 
malaria naïve blood donors (N = 8) and from malaria 
naïve patients with other parasitic infections (N = 15: 
n = 3 Leishmania spp., n = 4 Trypanosoma cruzi, n = 4 
Strongyloides stercoralis and n = 4 Schistosoma spp.) were 
also collected at CTD and included as negative controls.
Serum samples from candidate blood donors referring 
to the transfusion centres in Massa Carrara, Livorno, 
Lucca, Pisa and Viareggio—identified by the question-
naire as at-risk for malaria infection—were collected at 
the Parasitology Section of the Microbiology Unit of Pisa 
University Hospital (AOUP, Tuscany, Italy) between Feb-
ruary 2016 and February 2017, and screened with DRG 
ELISA (N = 496). The present study included N = 36 sera 
samples from screened candidate donors: all samples 
with a positive DRG result (n = 26), as well as random 
selection of samples with a negative DRG result (n = 10). 
All serum samples were stored at − 80 °C until use.
Immuno‑fluorescence antibody test (IFAT)
IFAT assay (Biomérieux Italia S.p.A.-Firenze) was per-
formed according to the manufacturer’s instructions. 
The target antigen of the assay consists of P. falciparum 
parasites obtained from in  vitro culture on human red 
cells and coated on slides. According to the manufac-
turer, the specificity and sensitivity of IFAT compared to 
another antibody detection method (i.e. electrosyneresis) 
or clinical symptoms are 98.74% (95% CI 95.43–99.66%) 
and 98.04% (95% CI 89.55–99.95%), respectively. The test 
enables the detection of Plasmodium-specific antibodies 
and samples are considered negative when IFAT titre = 0.
Enzyme linked immuno‑sorbent assay (ELISA)
Five commercial ELISA kits were employed to test 
serum samples: (1) Dia.Pro Malaria Ab (Diagnostics 
Probes—Srl, Italy); (2) DRG Malaria ELISA (DRG Diag-
nostics GmbH, Germany); (3) Novatec NovaLisa malaria 
(NovaTec Immundiagnostica GmbH, Germany); (4) 
Euroimmun Anti-Plasmodium ELISA (Euroimmun AG, 
Germany); (5) BioRad Malaria EIA Test (BioRad, CA, 
USA). All kits were obtained as a kind donation from 
their respective companies.
Dia.Pro malaria Ab
The kit is based on recombinant proteins representing 
immuno-dominant epitopes of Plasmodium spp. (with-
out species indication) and detects anti-Plasmodium IgG, 
IgM or IgA. The detection is based on a biotin-streptavi-
din-HRP system: recombinant Plasmodium spp. proteins 
are used at the bottom of the plate, for antibody-capture, 
and in a biotinylated form for the identification of the 
antigen–antibody complex.
DRG malaria ELISA and Novatec NovaLisa malaria
Both these kits use recombinant antigens from P. falcipa-
rum and P. vivax to detect IgG and IgM antibodies. Anti-
bodies against P. malariae and P. ovale are also detected 
due to antigenic similarity.
Euroimmun anti‑Plasmodium ELISA
Among the tested kits, the Euroimmun is the only one 
based on a mix of antigens from the five Plasmodium 
spp. most frequently infecting humans. Consequently, it 
detects IgG against P. falciparum, P. vivax, P. malariae, P. 
ovale and P. knowlesi.
BioRad malaria EIA test
The test uses HRP-conjugated Plasmodium proteins for 
the detection of the antigen–antibody complex, conse-
quently IgG, IgM and IgA anti P. falciparum and P. vivax 
can be detected. Antibodies against P. malariae and P. 
ovale can also be detected due to cross-reaction. Alter-
native names for this test can be found in the literature: 
Lab21 Healthcare or Lab21 Newmarket, depending on 
the distributor [21].
Internal positive and negative controls were provided 
in each kit and samples were manually processed accord-
ing to the manufacturer’s instructions. The internal valid-
ity of ELISA results was evaluated by checking the OD 
values of the internal control samples against the validity 
ranges specified in each kit, by building a standard curve 
using serial dilutions of a pool of hyperimmune sera, 
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and by estimating experimental precision and repro-
ducibility on duplicate samples (Additional file  1). The 
cut-off values were calculated, indexes were computed 
 (ODsample/ODcutoff × 10), and samples were classified as 
negative, positive or “grey zone” according to manufac-
turer’s instructions. Samples with a result falling in the 
“grey zone” cannot be defined as positive or negative and, 
according to the kits instructions, the subject should be 
tested again after a few weeks.
Study design and sample size
The sensitivity and specificity of the different ELISA kits 
was determined by testing sera (N = 64) from malaria 
patients and using IFAT as the reference standard. The 
specificity of the different ELISA kits was further exam-
ined by testing serum samples from malaria naïve indi-
viduals (N = 8 healthy subjects and N = 15 patients with 
other parasitic diseases). The agreement between ELISA 
and IFAT was further assessed by investigating the dis-
tribution of ELISA indexes and the proportion of posi-
tive ELISA results according to IFAT titre (0, 20, 80, 160, 
320, 640, 1280 and 2560, 5120 and 10,240; 8 samples 
per group). In order to further compare ELISA kits with 
IFAT, and in particular to investigate whether a positive 
relationship exists, as expected, the association of IFAT 
titres with ELISA quantitative (indexes) and qualita-
tive (positive/negative) results was assessed by graphical 
inspection.
The agreement between the five different ELISA kits 
was evaluated through the concordance between results 
of each pair of kits in samples from candidate blood 
donors (N = 36), in order to evaluate the probability that 
the same candidate donor will receive the same response 
independently of the kit used in the laboratory. The sam-
ple size was not formally calculated, as it was constrained 
by the number of tests supplied free of charge by the 
distributors.
Statistical analysis
Statistical analyses were performed in STATA v.15 (Stata-
Corp. 2017. Stata Statistical Software: Release 15. Col-
lege Station, TX: StataCorp LLC) and GraphPad Prism 
v7.02 (GraphPad Software, Inc., CA, USA). The accuracy 
(sensitivity, specificity and the corresponding 95% CI) of 
the ELISA kits was computed to establish the ability of 
each test to classify samples (N = 64) as positive or nega-
tive, when compared to IFAT results. Samples falling in 
the “grey zone” were excluded from these calculations. 
Concordance and Cohen’s k statistics were computed to 
assess the agreement of qualitative results between each 
pair of the five ELISA kits in the sample of candidate 
blood donors. A p-value < 0.05 was considered statisti-
cally significant.
Results
Comparison of ELISA and IFAT results
The ability of the five ELISA kits in classifying malaria 
serum samples as positive or negative for anti-Plas-
modium antibodies, compared to the IFAT reference 
standard is reported in Table  1 and Fig.  1. Among the 
N = 64 tested samples, those falling in the “grey zone” 
were excluded from these calculations, since a positive 
or negative result could not be assigned. The number of 
samples in the “grey zone” was 3 for the Dia.Pro kit, 1 for 
Novatec, 4 for Euroimmun and 2 for DRG. No relation 
between these samples and the IFAT titre was observed.
All kits showed 100% specificity (N = 8) and thus no 
false positive results. The sensitivity, instead, varied from 
53.6% (BioRad kit) to 64.2% (Dia.Pro kit). Overall, the 
Dia.Pro showed the best performance, among the tested 
kits (Table 1).
All sera (N = 23) from healthy subjects with no history 
of malaria exposure (n = 8) as well as from patients suf-
fering from other parasitic diseases (n = 15) resulted neg-
ative when tested with each of the five kits, confirming 
100% specificity as well as lack of cross-reactivity with 
non-Plasmodium-specific antibodies.
Figure  2 shows the distribution of ELISA indexes 
according to IFAT titre for every ELISA kit. ELISA 
indexes increased at higher IFAT titres for the DRG, 
Euroimmun and Novatec kits, as expected. However, 
for the DRG and Novatec kits a distribution of ELISA 
indexes values lower than expected was observed at 
IFAT titre 1:320, while for the Euroimmun kit there was 
Table 1 Performance of the five ELISA kits for the qualitative classification of malaria patients serum samples compared 
to IFAT
IFAT was considered as the reference standard: sensitivity was assessed in comparison to IFAT positive samples (N = 56) and specificity on IFAT negative samples 
(N = 8). Since samples with ELISA indexes falling in the “grey zone” were excluded from the analysis, the number of samples included for each test was as follows: 
BioRad n = 64; Dia.Pro n = 61; Euroimmun n = 60; Novatec n = 63; DRG n = 62
SE sensitivity, SP specificity, CI confidence interval
BioRad Dia.Pro Euroimmun Novatec DRG
%SE (95% CI) 53.6 (39.7–67) 64.2 (49.8–76.9) 56.6 (42.3–70.2) 54.5 (40.6–68) 55.6 (41.4–69.1)
%SP (95% CI) 100 (63.1–100) 100 (63.1–100) 100 (59–100) 100 (63.1–100) 100 (63.1–100)
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a wider distribution of ELISA indexes values in the IFAT 
titre range 1:1280–1:2560. Although for these three kits a 
positive linear relationship was observed between IFAT 
and ELISA measures, it was not possible to assign a given 
IFAT titre to a sample based on its ELISA index, due to 
some overlap in the indexes distribution. It was not pos-
sible to recognize an increase of ELISA indexes with 
IFAT titre and, therefore, a positive linear pattern, for the 
BioRad and Dia.Pro kits.
Figure 3 shows the percentage of positive ELISA results 
according to IFAT titre for every ELISA kit. ELISA posi-
tivity (%) increased at higher IFAT titres for the DRG, 
Euroimmun and Novatec kits, as expected, with a mini-
mum of 0% positivity at the lowest positive titre 1:20 
and a maximum of 100% positivity at the highest titre 
1:5120–1:10,240. However, for the DRG and Novatec 
kits a positivity lower than expected (i.e. no increase 
with respect to the previous titre) was observed at titres 
1:320 and 1:1280–1:2560, while for the Euroimmun kit 
such deviation from expectation was observed at titre 
1:1280–1:2560. For the BioRad and Dia.Pro kits, a mini-
mum positivity was observed at the lowest titre, but at 
the other titres the pattern of positivity was not clearly 
linearly related to IFAT values.
Comparison of ELISA kits for the screening of serum 
samples from candidate blood donors
The five ELISA kits were used to analyse serum samples 
from candidate blood donors and to compare their abil-
ity in classifying subjects as negative or positive at TTM 
screening. The concordance among the qualitative results 
of different ELISA kits is shown in Table  2. The paired 
kits showed variable agreement in the 41.7–94.4% range 
and k ranged from poor (0.1572, p = 0.0234) to very high 
(0.8750, p < 0.0001). Furthermore, only 12 out of 36 sam-
ples (33%) were identically classified as positive or nega-
tive by the five kits. The agreement between assays was 
not affected by the country of birth (malaria-endemic 
vs non-endemic) of candidate blood donors nor by the 
result (positive vs negative) of the original screening test 
(data not shown). Repeatability data for the DRG assay 
are presented in Additional file 1.
Fig. 1 Qualitative comparison of the results obtained with ELISA and 
IFAT. The results obtained with the five ELISA kits and with the IFAT 
reference standard on N = 64 serum samples from malaria patients are 
reported. For IFAT, samples were classified as negative if IFAT titre = 0, 
or positive if IFAT titre ≥ 20; IFAT titres are reported on the left of the 
graph. For ELISA, samples were classified as negative, positive or “grey 
zone” according to the indications of the manufacturer of each kit
◂
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Discussion
Serological methods are currently employed in Italy and 
other non-endemic countries for the screening of can-
didate blood donors in order to detect potential asymp-
tomatic carriers of Plasmodium parasites and prevent 
transfusion-transmitted malaria [2, 5]. According to the 
National regulation, Italian laboratories can adopt differ-
ent serological assays for the detection of Plasmodium-
specific antibodies [13]. The aim of the present study 
was to evaluate and compare five commercial ELISA kits 
for the detection of anti-Plasmodium antibodies in both 
malaria patients and candidate blood donors.
Overall, the five ELISA kits showed unsatisfactory sen-
sitivity (below 65%) for the classification of malaria sam-
ples, as compared to the Biomérieux IFAT, as reference 
test. Although no cross-reactivity with other parasitic 
infections was observed, such a low sensitivity indicates 
that these kits are inadequate to achieve an accurate 
detection of samples positive for the presence of anti-
Plasmodium antibodies, due to the high proportion of 
false negative results [22–27].
The sensitivity of ELISA assays compared to IFAT 
among malaria patients’ samples has been previously 
assessed by three studies, all evaluating the Cellabs 
ELISA kit [22–24]. In the larger and most recent study 
(n = 144), conducted by Silvie and colleagues, a similar 
sensitivity to the present study was found (57%) com-
pared to an in-house IFAT method, and the authors 
observed that ELISA sensitivity increased at higher 
IFAT titres [24]. In the first study by Chiodini and col-
leagues (n = 56), a very high sensitivity (93%) had been 
observed compared to an in-house IFAT method [22], 
but this result was not replicated in the following study 
by Mertens and colleagues (n = 49), where a higher 
although insufficient sensitivity (71%) was observed 
compared to Biomerieux IFAT [23]. A further evi-
dence that ELISA sensitivity is insufficient to identify at 
risk donors is provided by a case of TTM occurred in 
2015 in Georgia, USA, where the donor had a negative 
ELISA result [28].
When assessed on candidate blood donors’ samples, 
the five kits showed highly variable results, with a per-
centage agreement varying from poor to high, depend-
ing on the pair of kits. It is therefore possible that a 
candidate blood donor will receive a different response 
from laboratories using different ELISA kits, with a 
probability depending on the kits pair, implying that a 
candidate blood donor could be considered suitable for 
or excluded from donation, depending on the kit in use 
in the reference laboratory.
The present study is based on a limited sample size, 
which affects the precision of the estimates, and limits 
Fig. 2 Distribution of ELISA indexes according to IFAT titres. The Figure shows, for each ELISA kit under study, a Tukey box-plot describing the 
distribution of ELISA indexes  (ODsample/ODcutoff × 10), according to IFAT titre. For each category represented, N = 8
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the generalizability of the results. Also, only ELISA kits 
commercially available in Italy at the time of the study 
were evaluated, and other products might show differ-
ent characteristics. However the data presented here 
should provide evidence that the tested commercial 
ELISA kits are unsuitable—in particular if employed 
individually—for the screening of candidate blood 
donors for TTM risk.
Conclusion
Semi-immune individuals represent the biggest chal-
lenge for blood safety and TTM screening as they might 
become asymptomatic carriers with a very low parasite 
density, which is difficult to detect with current direct 
diagnostic methods. Seed and colleagues reported that 
parasite densities as low as 1–10 parasites per blood unit 
are estimated to be sufficient to generate a malaria infec-
tion in a naïve recipient, albeit such levels are far from 
being detected by current methods, including PCR [6, 
29]. Therefore, serological examination, combined with 
donors’ questionnaire, has been considered the most 
effective and sensitive screening method in non-endemic 
countries, although not ideal [6, 30].
In agreement with the literature, the present results 
highlight the need for the development of more sensi-
tive serological tests, which should also be highly spe-
cific and reproducible. Moreover, future revisions, or 
application guidelines, of the current recommendations 
should include specific indication regarding which ELISA 
kit(s) should be adopted by the laboratories for TTM 
risk screening, in order for serology results and donors 
screening to be uniform and reproducible at national 
level.
To ensure blood safety and blood supply, the screen-
ing strategy may benefit from the use of multiple tests 
including more sensitive serological tests and molecular 
methods for the detection of Plasmodium spp. nucleic 
acids [31]. With the objective of establishing an accurate 
method for blood testing, Kitchen and colleagues have 
recently tested a screening algorithm which combines 
the use of different screening and confirmatory tests to 
detect parasitaemic blood donors, suggesting that a com-
bination of multiple tests might be required to ensure 
Fig. 3 Frequency of ELISA positive results according to IFAT titre. The Figure shows, for each ELISA kit under study, the frequency of positive results 
according to IFAT titre. For each category represented, N = 8
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safety of blood transfusions [1]. Such an approach would 
contribute to guarantee a safe blood supply avoiding the 
exclusion of suitable blood donors and, consequently, the 
loss of donations of rare blood.
Additional file
Additional file 1. Internal validity of ELISA kits. Agreement between 
results of first and second DRG tests.
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